GPCR
GPCR clinical trials: Structure Therapeutics Inc.
Every trial on ClinicalTrials.gov where Structure Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 12
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GPCR on the catalyst calendar · GPCR registry changes
- Primary completion Mar 2027Sponsor estimatePhase 1NCT07946068Aleniglipron Renal Impairment StudyGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Renal ImpairmentNot yet recruitingGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT07872033Aleniglipron Hepatic Impairment StudyGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Hepatic ImpairmentRecruitingGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT07654374A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · ObesityRecruitingGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2026ActualPhase 2NCT07400588Aleniglipron Phase 2 in Type 2 Diabetes MellitusGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · ObeseCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 9, 2026ActualPhase 2NCT07169942Aleniglipron Phase 2 Body Composition StudyGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, or Chronic Weight ManagementCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1/Phase 2NCT07815678First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics · ObesityRecruitingGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT07654361Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · ObesityRecruitingGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2025ActualPhase 2NCT06693843A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living...Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, or Chronic Weight ManagementCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2026ActualPhase 2NCT06703021A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related...Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · ObesityCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2024ActualPhase 1/Phase 2NCT05762471Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Overweight or ObesityCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2024Sponsor estimatePhase 1NCT06139055A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Healthy VolunteersUnknown statusGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2023ActualPhase 1NCT05893043A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy ParticipantsGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Healthy VolunteersCompletedGPCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner